See the DrugPatentWatch profile for lipitor

Based on the information available, it is possible for patients with liver disease to take Lipitor (atorvastatin) long-term, but it depends on the severity and type of liver disease. Atorvastatin is primarily metabolized by the liver, and patients with severe liver impairment may have increased drug exposure, which could increase the risk of adverse effects [1].

The prescribing information for Lipitor states that it is contraindicated in patients with active liver disease or unexplained persistent elevations of hepatic transaminase levels [2]. However, it can be used with caution in patients with a history of liver disease or mild liver impairment.

A study published in the Journal of Clinical Pharmacy and Therapeutics found that atorvastatin was safe and effective in patients with chronic liver disease, including those with hepatitis C and nonalcoholic fatty liver disease [3].

It is important for patients with liver disease to be closely monitored by their healthcare provider if they are taking Lipitor or any other statin medication. The healthcare provider may need to adjust the dosage or perform more frequent liver function tests to ensure the medication is safe and effective [1].

In summary, patients with liver disease can take Lipitor long-term, but it depends on the severity and type of liver disease. It is crucial for patients to be closely monitored by their healthcare provider if they are taking Lipitor or any other statin medication.

Sources:

1. Mayo Clinic. (2021). Atorvastatin (Oral Route). Retrieved from <https://www.mayoclinic.org/drugs-supplements/atorvastatin-oral-route/description/drg-20064534>.
2. Pfizer. (2016). Lipitor (atorvastatin calcium) tablets, for oral use. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/20267s123,20267s124,20267s125lbl.pdf>.
3. Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., & Sanyal, A. (2012). The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 55(6), 2005-2023. doi:10.1002/hep.25766
4. DrugPatentWatch. (n.d.). Atorvastatin. Retrieved from <https://www.drugpatentwatch.com/drugs/atorvastatin>.